235 related articles for article (PubMed ID: 30939771)
1. Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy.
Barré A; Azzouz R; Gembus V; Papamicaël C; Levacher V
Molecules; 2019 Apr; 24(7):. PubMed ID: 30939771
[TBL] [Abstract][Full Text] [Related]
2. Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine "bio-oxidizable" prodrugs: Synthesis, biological evaluation and structure-activity relationship.
Azzouz R; Peauger L; Gembus V; Ţînţaş ML; Sopková-de Oliveira Santos J; Papamicaël C; Levacher V
Eur J Med Chem; 2018 Feb; 145():165-190. PubMed ID: 29324339
[TBL] [Abstract][Full Text] [Related]
3. Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation.
Peauger L; Azzouz R; Gembus V; Ţînţaş ML; Sopková-de Oliveira Santos J; Bohn P; Papamicaël C; Levacher V
J Med Chem; 2017 Jul; 60(13):5909-5926. PubMed ID: 28613859
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
5. Rational design of carbamate-based dual binding site and central AChE inhibitors by a "biooxidisable" prodrug approach: Synthesis, in vitro evaluation and docking studies.
Ţînţaş ML; Gembus V; Alix F; Barré A; Coadou G; Truong L; Sebban M; Papamicaël C; Oulyadi H; Levacher V
Eur J Med Chem; 2018 Jul; 155():171-182. PubMed ID: 29886321
[TBL] [Abstract][Full Text] [Related]
6. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
7. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer's Disease.
Toublet FX; Lecoutey C; Lalut J; Hatat B; Davis A; Since M; Corvaisier S; Freret T; Sopkova de Oliveira Santos J; Claeysen S; Boulouard M; Dallemagne P; Rochais C
Molecules; 2019 Jul; 24(15):. PubMed ID: 31370232
[TBL] [Abstract][Full Text] [Related]
9. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
Meine R; Becker W; Falke H; Preu L; Loaëc N; Meijer L; Kunick C
Molecules; 2018 Jan; 23(2):. PubMed ID: 29364148
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT
Toublet FX; Lalut J; Hatat B; Lecoutey C; Davis A; Since M; Corvaisier S; Freret T; Sopková-de Oliveira Santos J; Claeysen S; Boulouard M; Dallemagne P; Rochais C
Eur J Med Chem; 2021 Jan; 210():113059. PubMed ID: 33310288
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946
[TBL] [Abstract][Full Text] [Related]
12. Dihydroquinoline Carbamate Derivatives as "Bio-oxidizable" Prodrugs for Brain Delivery of Acetylcholinesterase Inhibitors: [¹¹C] Radiosynthesis and Biological Evaluation.
Bohn P; Gourand F; Papamicaël C; Ibazizène M; Dhilly M; Gembus V; Alix F; Ţînţaş ML; Marsais F; Barré L; Levacher V
ACS Chem Neurosci; 2015 May; 6(5):737-44. PubMed ID: 25695305
[TBL] [Abstract][Full Text] [Related]
13. Total Synthesis of Pulmonarin B and Design of Brominated Phenylacetic Acid/Tacrine Hybrids: Marine Pharmacophore Inspired Discovery of New ChE and Aβ Aggregation Inhibitors.
Cheng ZQ; Song JL; Zhu K; Zhang J; Jiang CS; Zhang H
Mar Drugs; 2018 Aug; 16(9):. PubMed ID: 30134630
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase.
Wang DM; Feng B; Fu H; Liu AL; Wang L; Du GH; Wu S
Molecules; 2017 Jan; 22(1):. PubMed ID: 28117700
[TBL] [Abstract][Full Text] [Related]
15. A molecular approach in drug development for Alzheimer's disease.
Agatonovic-Kustrin S; Kettle C; Morton DW
Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
[TBL] [Abstract][Full Text] [Related]
16. Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity.
Markowicz-Piasecka M; Sikora J; Mateusiak Ł; Mikiciuk-Olasik E; Huttunen KM
Oxid Med Cell Longev; 2017; 2017():7303096. PubMed ID: 28770024
[TBL] [Abstract][Full Text] [Related]
17. Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-D-sedoheptulose derived from Corni fructus as cholinesterase and β-secretase 1 inhibitors.
Bhakta HK; Park CH; Yokozawa T; Min BS; Jung HA; Choi JS
Arch Pharm Res; 2016 Jun; 39(6):794-805. PubMed ID: 27106028
[TBL] [Abstract][Full Text] [Related]
18. Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
Kumar B; Kumar V; Prashar V; Saini S; Dwivedi AR; Bajaj B; Mehta D; Parkash J; Kumar V
Eur J Med Chem; 2019 Sep; 177():221-234. PubMed ID: 31151057
[TBL] [Abstract][Full Text] [Related]
19. New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
Larik FA; Shah MS; Saeed A; Shah HS; Channar PA; Bolte M; Iqbal J
Int J Biol Macromol; 2018 Sep; 116():144-150. PubMed ID: 29729344
[TBL] [Abstract][Full Text] [Related]
20. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
